Colorectal cancer vaccine - Immunovo/Pepscan Therapeutics

Drug Profile

Colorectal cancer vaccine - Immunovo/Pepscan Therapeutics

Latest Information Update: 08 Apr 2016

Price : $50

At a glance

  • Originator Pepscan Systems
  • Developer Immunovo; Pepscan Therapeutics; VU University Medical Center
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Colorectal cancer

Most Recent Events

  • 24 Mar 2009 Preclinical development is ongoing in the Netherlands
  • 21 Mar 2006 Preclinical trials in Colorectal cancer in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top